Trusted veterinary advice and products
This product requires a prescription from your veterinary surgeon. click here

Cerenia Tablets can be used to treat or prevent nausea or vomiting in dogs, alongside other appropriate therapies. It can also be used in dogs to alleviate nausea associated with chemotherapy or motions sickness |e.g. car travel.).

Brand

Cerenia

Manufacturer

Zoetis

Species

Dog

Prescription Type

POM-V (Written prescription required)

£26.65
Reference : Med-6795147
Delivery Between 2 and 3 days
  • Description
  • Properties
  • Packaging
  • Ingredients
  • Directions
  • Legal notice
  • Customer Reviews
  • Further advice

Cerenia Tablets are used to treat vomiting in dogs or to prevent vomiting in dogs, in combination with other supportive measures. The tablets can also be used to prevent vomiting due to motion sickness in dogs.

Cerenia works by blocking the neurokinin-1 (NK1) receptors, which are found on the surface of certain cells in the part of the brain that controls nausea and vomiting and are activated by the attachment of a chemical in the body called ‘substance P’. By preventing the attachment of substance P to the receptors, Cerenia prevents them from being activated and so reduces nausea and vomiting.

Indications for use


For the prevention of nausea induced by chemotherapy.

For the treatment and prevention of vomiting, in conjunction with Cerenia Solution for Injection and in combination with other supportive measures.

For the prevention of vomiting induced by motion sickness.

 

 

This is a prescription only medicine (POM-V)

Cerenia is only available with a prescription from your veterinary surgeon.

To check the most up to date information about this product, please read its Summary of Product Characteristics (SPC) below:

http://www.vmd.defra.gov.uk/ProductInformationDatabase/Default.aspx

Pharmaceutical precautions

 

This veterinary medicinal product does not require any special storage conditions.

Half-tablets should be stored for a maximum of two days after removal from the blister. Half-tablets should be returned to the opened blister and kept within the cardboard outer.

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Keep out of the sight and reach of children.

For animal treatment only.

4 tablets

Active substances:

Maropitant (as maropitant citrate monohydrate): 160mg

Cerenia is a prescription product and must be used according to the instructions of your veterinary surgeon.

Please read the product leaflet thoroughly before giving to your pet.

Marketing Authorisation Holder

 

Zoetis Belgium SA
Rue Laid Burniat 1
1348 Louvain-la-Neuve
BELGIUM

 

Marketing Authorisation Number

 

EU/2/16/062/001-004

Contra-indications

 

Vomiting can be associated with serious, severely debilitating conditions including gastrointestinal obstructions; therefore, appropriate diagnostic evaluations should be employed.

Administering Cerenia on a completely empty stomach may cause the dog to vomit. A light snack before dosing could help prevent this effect.

The safety of Cerenia has not been established in dogs less than 16 weeks of age (for the 8 mg/kg dose: motion sickness) and in dogs less than 8 weeks of age (for the 2 mg/kg dose: vomiting), as well as in pregnant or lactating bitches. Use only according to a risk benefit assessment by the responsible veterinary surgeon.

Cerenia should be used in conjunction with other supportive measures if appropriate.

Cerenia tablets were well tolerated when administered for 15 days at dosages up to 10 mg/kg bodyweight per day. Clinical signs including vomiting on first administration, excess salivation and watery faeces have been observed when the product has been overdosed in excess of 20 mg/kg.

The safety of maropitant during treatment beyond 5 days has not been explored in young dogs with viral enteritis. In case treatment for a longer period than 5 days is required, careful monitoring of potential adverse events should be implemented.

Maropitant is metabolised in the liver and therefore should be used with caution in dogs with liver disease. As maropitant is accumulated in the body during a 14 day treatment period due to metabolic saturation, careful monitoring of liver function in addition to any adverse events should be implemented during long term treatment.

Cerenia should be used with caution in animals suffering from or with a predisposition for heart diseases. Cerenia should not be used concomitantly with Ca-channel antagonists as maropitant has affinity to Ca-channels.

Maropitant is highly bound to plasma proteins and may compete with other highly bound drugs.

Cerenia is not a sedative and some motion sick dogs may show nausea-like signs during travel such as salivation and lethargy. These signs are temporary and should resolve when the journey ends.

Incidents of pre-travel vomiting, usually within two hours post-dosing, were commonly reported (more than 1 but less than 10 animals in 100 animals treated) after administration of the 8 mg/kg dose.

 

User warnings:

 

People with known hypersensitivity to maropitant should administer the veterinary medicinal product with caution.

Wash hands after use. In case of accidental ingestion seek medical advice immediately and show the package leaflet or the label to the physician.